Biomarkers of Alzheimer's disease risk in peripheral tissues; focus on buccal cells

Maxime François
*Edith Cowan University*, maxime.francois@csiro.au

Wayne Leifert

Ralph Martins
*Edith Cowan University*, r.martins@ecu.edu.au

Philip Thomas

Michael Fenech

Follow this and additional works at: [https://ro.ecu.edu.au/ecuworkspost2013](https://ro.ecu.edu.au/ecuworkspost2013)

Part of the Neurosciences Commons

**Recommended Citation**
François, M., Leifert, W., Martins, R., Thomas, P., & Fenech, M. (2014). Biomarkers of Alzheimer’s disease risk in peripheral tissues; focus on buccal cells. DOI: [https://doi.org/10.2174/1567205011666140618103827](https://doi.org/10.2174/1567205011666140618103827)

[10.2174/1567205011666140618103827](https://doi.org/10.2174/1567205011666140618103827)

Francois M., Leifert W., Martins R., Thomas P., & Fenech M. (2014). Biomarkers of Alzheimer’s disease risk in peripheral tissues; focus on buccal cells. Current Alzheimer Research, 11(6), 519-531. The published manuscript is Available at EurekaSelect [here](https://doi.org/10.2174/1567205011666140618103827)

This Journal Article is posted at Research Online. [https://ro.ecu.edu.au/ecuworkspost2013/249](https://ro.ecu.edu.au/ecuworkspost2013/249)
Title:

Biomarkers of Alzheimer’s disease risk in peripheral tissues; focus on buccal cells

Authors:

Maxime François\textsuperscript{1,2,3}, Wayne Leifert\textsuperscript{1,2}, Ralph Martins\textsuperscript{3}, Philip Thomas\textsuperscript{1,2}, Michael Fenech\textsuperscript{1,2}

\textsuperscript{1}CSIRO Animal, Food and Health Sciences, Adelaide, South Australia, 5000, Australia.
\textsuperscript{2}CSIRO Preventative Health Flagship, Adelaide, South Australia, 5000, Australia.
\textsuperscript{3}Edith Cowan University, Centre of Excellence for Alzheimer’s Disease Research and Care, Joondalup, Western Australia, 6027, Australia.

Running Title:

Peripheral Biomarkers of Alzheimer’s Disease

Corresponding Authors:

Wayne Leifert
CSIRO Animal, Food and Health Sciences.
Gate 13, Kintore Ave,
Adelaide, South Australia, 5000,
Australia.
Phone: (08) 8303 8821 / Email: wayne.leifert@csiro.au

Michael Fenech
CSIRO Animal, Food and Health Sciences.
Gate 13, Kintore Ave,
Adelaide, South Australia, 5000,
Australia.
Phone: (08) 8303 8880 / Email: michael.fenech@csiro.au
Abstract

Alzheimer’s disease (AD) is a progressive degenerative disorder of the brain and is the most common form of dementia. To-date no simple, inexpensive and minimally invasive procedure is available to confirm with certainty the early diagnosis of AD prior to the manifestations of symptoms characteristic of the disease. Therefore, if population screening of individuals is to be performed, more suitable, easily accessible tissues would need to be used for a diagnostic test that would identify those who exhibit cellular pathology indicative of mild cognitive impairment (MCI) and AD risk so that they can be prioritized for primary prevention. This need for minimally invasive tests could be achieved by targeting surrogate tissues, since it is now well recognized that AD is not only a disorder restricted to pathology and biomarkers within the brain. Human buccal cells for instance are accessible in a minimally invasive manner, and exhibit cytological and nuclear morphologies that may be indicative of accelerated ageing or neurodegenerative disorders such as AD. However, to our knowledge there is no review available in the literature covering the biology of buccal cells and their applications in AD biomarker research. Therefore, the aim of this review is to summarize some of the main findings of biomarkers reported for AD in peripheral tissues, with a further focus on the rationale for the use of the buccal mucosa (BM) for biomarkers of AD and the evidence to date of changes exhibited in buccal cells with AD.

Keywords

Alzheimer’s disease, peripheral biomarkers, buccal mucosa, mild cognitive impairment, diagnosis.
1. Need for predictive biomarkers of AD

Alzheimer’s disease (AD) is the sixth leading cause of death in the United States [1] and the most common form of dementia. AD patients have been reported with cognitive impairment characterized by impaired ability to register new information, reasoning, visuospatial abilities and language functions. AD patients also exhibit behavioural symptoms such as for instance, mood fluctuations, apathy, compulsive or obsessive behaviours and loss of interest, often correlated with loss of cognitive functions [2-5]. Previously, clinical diagnosis of AD were based upon criteria outlined by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA), published in 1984 including memory impairments, visuospatial and language impairment (aphasia) as measured by the Mini-Mental State Examination (MMSE) [6]. These criteria were recently revised by the NINCDS-ADRDA to incorporate biomarkers of brain amyloid-beta (cerebrospinal fluid (CSF) Amyloid-β 1-42, positive positron emission tomography (PET) amyloid imaging) and downstream neuronal degeneration (CSF Tau, magnetic resonance imaging of brain atrophy, PET imaging of fluorodeoxyglucose uptake) in the diagnosis of AD [5]. Although NINCDS-ADRDA does not encourage the use of such biomarkers within tests for routine diagnostic purposes, they can and should be used to increase certainty of diagnostic in research and clinical trials. However, the current suite of tests used in clinical diagnosis can only provide a possible or probable diagnostic of AD in living subjects and the definitive diagnostic can only be made during post-mortem. This is achieved by the observation of the extracellular senile plaques and intracellular neurofibrillary tangles in the specific areas of the brain such as the entorhinal cortex and hippocampus [7,8]. The number of new AD cases is dramatically increasing with an estimated 81.1 million people worldwide being affected by dementia by 2040 [9] and since the pathogenic processes of AD are likely to begin years before clinical symptoms are observed, the need of predictive biomarkers has become urgent. Moreover
AD does not only alter the quality of life, health and wellbeing of those affected but also leads to a significant social financial burden [10,11].

2. Peripheral tissue as source for AD biomarkers

A biomarker, as defined by the National Institutes of Health Biomarkers Definitions Working Group, is “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” [12]. A potential biomarker should be useful for detecting early stages of a disease and exhibit high levels of sensitivity and specificity. The scientific community has been actively investigating potential early biomarkers of AD. Currently, the majority of investigators have used blood, CSF or brain imaging. In terms of direct brain imaging, Pittsburgh B (PiB) compound was used and shown to be able to readily detect amyloid-β (Aβ) protein aggregation forming senile plaques in specific regions of the brain, however it has been shown in some case reports that the accumulation of large plaques are necessary for PiB imaging to be useful [13,14]. Additionally, CSF has been used to identify changes in Aβ42 and Tau protein levels [15,16]. However, these methods of investigations are not ideal for screening populations since they are either too invasive and/or expensive [15,17,18]. Therefore, if screening of populations of individuals for the early detection of AD is to be performed, more suitable, easily accessible tissues need to be utilized introducing diagnostic tests at much lower costs together with high specificity and sensitivity. This need for minimally invasive tests could be achieved by targeting surrogate tissues reflecting systemic susceptibility as recent evidence indicates that AD is a disorder that is not completely restricted to pathology and biomarkers within the brain, but significant biological changes also appear in non-neural tissues such as fibroblasts, blood and buccal cells [19-23] and is summarized in Table 1.
2.1. Fibroblasts

The plausibility that AD risk is reflected in cellular biomarkers in peripheral tissue has been investigated by studying well-known markers of genomic instability that have been reported to increase with age, and therefore suggest that the capacity for repair of DNA damage may also be altered in AD [24-26]. Micronuclei (MN) are a well validated and robust biomarker of whole chromosome loss and/or breakage that originate from chromosome fragments or whole chromosomes that lag behind at anaphase during nuclear division and have been shown to be predictive of increased cancer risk, cardiovascular mortality and have been found to be elevated in neurodegenerative disorders [27-30]. In fibroblasts for example, MN frequency has been shown to be increased with advancing age [31] as well as in AD [32].

Down’s syndrome is also considered a premature ageing syndrome with a high rate of conversion to dementia and is associated with abnormally high levels of DNA damage [33,34]. Furthermore, Down’s syndrome (trisomy 21) patients express brain changes by their 4th decade of life that are histopathologically indistinguishable from AD [35]. As the amyloid-β protein precursor (AβPP) gene is encoded on chromosome 21 [36], it has been suggested that one of the underlying mechanisms of AD could be the altered gene dosage and subsequent expression of AβPP, leading to accumulation of the aggregating form of Aβ peptide following proteolysis. Peripheral tissue such as skin fibroblasts from familial and sporadic AD has been shown to exhibit a 2-fold increase in the number of trisomy 21 cells when compared to controls [35]. Moreover, an increase in immunostaining of amyloid peptides (Aβ40, Aβ42) as well as an imbalance between free cholesterol and cholesterol ester pools has been observed in fibroblasts of AD [37]. The capacity of fibroblasts to spread in culture was also observed to be altered in AD with a decrease of cytosolic free calcium (p<0.001) [38]. Furthermore an increase of total bound calcium in fibroblasts was observed when compared to age-matched controls [39].
2.2. Olfactory epithelium

Anosmia or olfactory dysfunction resulting in loss of smell is common in neurodegenerative diseases such as Parkinson’s or AD and may appear as one of the early symptoms. Furthermore, olfactory dysfunction has been found to be commonly associated with memory deficiency in transgenic mouse models of AD [40,41]. In humans, the olfactory epithelium was shown to be a peripheral tissue that exhibited increased oxidative damage in AD. HNE-pyrrole (a product of lipid oxidation) and heme oxygenase-1 (a catalytic enzyme involved in degradation of heme) levels were found to be increased in neurons and epithelial cells from olfactory biopsy sections in AD compared to healthy controls (p<0.002 and p<0.0001, respectively), thus confirming the presence of oxidative damage at a peripheral level in AD [42]. Increased levels of Aβ and hyperphosphorylated Tau were also observed in the olfactory epithelium in AD [21]. Detection was performed by immunohistochemistry and a significant increase in frequency of both Aβ (p<0.001) and hyperphosphorylated Tau (p<0.05) was observed when compared to controls [21]. Post-mortem neuropathological examination of participants’ brains were also undertaken and a significant correlation (r = 0.37, p<0.001) was found between Aβ plaque frequency in olfactory epithelium and averaged Aβ frequency in multiple cortical regions (i.e. hippocampus, entorhinal cortex, amygdala, superior/middle temporal gyri, angular gyrus, mid-frontal gyrus, and anterior cingulate cortex) [21]. Additionally, there was a significant correlation found between hyperphosphorylated Tau in olfactory epithelium and hyperphosphorylated Tau in brains (p<0.05) [21]. Therefore, the presence of Aβ and Tau immunostaining could also be investigated in peripheral tissue such as olfactory epithelium for potential early AD biomarkers.

2.3. Whole blood
Since blood can be sampled easily and may reflect pathological changes in AD, it is not surprising that this tissue has been commonly investigated as a source for AD biomarkers [43-45]. For instance, following completion of a genome-wide association study (Alzheimer’s Disease Neuroimaging Initiative) [46], TOMM40 (translocase of outer mitochondrial membrane 40) was found to be a potential gene associated with AD (TOMM40 risk alleles were two times more frequent than in controls) and therefore an additional risk for developing AD [46]. The expression of this gene has been found to be significantly down-regulated in blood from AD compared to controls [44]. Another study, the Australian, Imaging, Biomarkers and Lifestyle study (AIBL) observed lower levels of red blood cell folate in AD patients compared to healthy controls (p=0.004), albeit serum folate did not show significant differences [47]. A recent study conducted by Leidinger et al. identified 140 differentially expressed microRNAs (mi-RNAs), non-coding RNAs that play key roles in the regulation of gene expression, in blood of Alzheimer’s patients when compared to controls and further validated a 12-miRNAs signature of AD [48]. Using this newly developed signature, AD patients were separated from the control group with 95.1% specificity and 91.5% sensitivity. Additionally, this signature presented a separation of MCI versus control with 81.1% specificity and 87.7% sensitivity [48]. Although these studies on whole blood samples have shown interesting results, studies on blood components (i.e. white blood cells, platelets and plasma) have also brought to light several promising findings as discussed below.

2.4. White blood cells

Tau protein, one of the main proteins known to be associated with AD interacts with microtubules, actin filaments and intermediate filaments to play a key role in regulating the organisation and integrity of the cytoskeleton [49]. An increase in the phosphorylation levels of Tau was reported to occur due to the compromised function of protein phosphatase 2A in
AD brains [50,51]. Tau protein was shown to be elevated in CSF of AD patients and is an accepted biological marker of AD [15,16]. In lymphocytes, both phosphorylated and non-phosphorylated forms of Tau were detected by Western blot and shown to be significantly increased in AD compared to controls (approximately 2-fold increase), with a direct correlation between phosphorylated Tau and disease duration [52]. Another protein, chitotriosidase (chitinase) a chitinolytic enzyme secreted by activated mononucleated cells that has previously been shown to exhibit a higher activity in CSF in AD [53,54], also showed a significantly increased level of expression (19-fold) in macrophages [55]. Evidence of the nuclear accumulation of γH2AX, a protein that becomes phosphorylated following induction of DNA double strand breaks, has been observed in astrocytes of AD brains [56]. Peripheral DNA damage, including single and double strand breaks, has been shown to increase in leukocytes of MCI and AD when compared to controls (p<0.001) [57]. Individuals with MCI have also been used to study biomarkers of AD since this group shows an approximate 50% of conversion into AD over 4 years [58] and it is interesting to note that the level of primary DNA damage is lower, although not significant, in AD compared with MCI [57]. This is suggestive that this type of DNA damage decreases as the disease progresses further.

Oxidative stress which results in the accumulation of oxidized DNA base adduct 8-hydroxy-2-deoxyguanosine (8-OHdG) is also believed to be involved in a number of neurodegenerative diseases [59-61] and has been shown to occur prior to the pathology hallmarks of AD [62]. An approximate 5-fold increase in 8-OHdG was observed in CSF of AD compared with controls (p<0.001) and may partly explain the DNA damage that has been observed in AD cases [63]. The comet assay, which can be used to assess both single and double strand breaks in DNA, has also been utilized after enzyme treatment to demonstrate that peripheral leukocytes exhibit a significant increase in oxidative DNA damage markers i.e. oxidized DNA pyrimidines and purines in MCI and AD with respect to controls (p<0.002 and p<0.001, respectively) [57]. More evidence has come from genomic instability markers
such as MN which were shown to increase in frequency in lymphocytes with age [64] and AD when compared to healthy controls [22,65,66].

Another marker of genetic instability, telomere length, is known to change with ageing and in some cell types involves progressive telomere shortening. Telomeres are highly conserved DNA sequence repeats (of TTAGGG) involved in the maintenance of genome stability. Telomere length can be assessed by a variety of methods including southern blot, flow cytometry, quantitative fluorescence in situ hybridisation (FISH) or by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) [67-70]. Shortened telomeres in blood have been shown to be associated with an increased risk of cardiovascular disease and degenerative disease such as cancers [71-73]. Telomere length has also been investigated in white blood cells of confirmed AD cases and found to be significantly shorter in those of AD patients compared with young and old controls (p<0.0001) [19]. Studies have shown a decrease in telomere length in lymphocytes isolated from AD that was correlated (r = -0.77) with a decrease in the MMSE scores indicating a possible link between telomere length and cognitive decline in AD [74].

Lymphocytes from AD cases or first degree relatives also show substantial differences relative to controls with respect to intracellular lipid pods [75]. Oil Red O (ORO) staining (indicative of accumulation of neutral lipids) has been used to demonstrate higher levels of neutral lipids in peripheral blood mononuclear cells of probable AD patients [75]. The study by Pani et al. 2009 demonstrated that approximately 85% of isolated lymphocytes from AD had high neutral lipids levels (mainly cholesterol ester) as well as an increased content of the Acetyl-Coenzyme A acetyltransferase-1 protein (the enzyme that catalyses the formation of cholesterol esters in cells) compared with cognitively normal age-matched controls. These
data suggest that intracellular cholesterol ester levels are systemically increased in AD patients and support the hypothesis of altered lipid metabolism in AD.

AD pathology has also been linked to proteins that are involved in maintaining the cell-cycle. For example hyperphosphorylated Tau is linked to the activity of cyclin-dependent protein kinases [76,77]; AβPP metabolism is monitored by cell-cycle dependent changes and is also up-regulated by mitogenic stimulation [78-80]; and finally Aβ (a product of AβPP processing) has been identified as mitogenic in in vitro studies [81,82]. A recent study using lymphocytes from AD patients demonstrated the potential of G1/S checkpoint proteins as biomarkers of AD. In that study, increased expression of Cyclin E, Rb, CDK2 and E2F-1 was observed and gave specificity/sensitivity scores of 84/81%, 74/89%, 80/78% and 85/85%, respectively [83]. These studies suggest that altered cell-cycle mechanisms may be indirectly involved in the process of AD onset and development.

2.5. Platelets

Platelets have also been investigated in AD and found to express changes with the disease state. For instance the ratio of two isoform products of AβPP processing (130kDa/110kDa) that occurs in platelets was studied as a potential biomarker and found to be decreased in platelet membranes in AD and MCI compared with their respective controls [84,85]. The presence of phosphorylated and non phosphorylated Tau protein was detected by immunofluorescence as well as different variant forms of Tau using Western blot techniques. The different immunoreactive fractions of Tau separated by Western were combined to obtain a ratio of high (>80 kDa) and low (<80 kDa) molecular weight bands and when quantified by imaging was found to be significantly increased in AD compared to healthy controls (p=0.0001) [23]. The results from this study confirmed that peripheral markers such as platelet Tau isoforms could serve as potential biological markers of AD.
2.6. Plasma

Plasma is obtained with relative ease and has been used widely to identify potential biomarkers of AD. Plasma sampled from AD individuals has previously shown an approximate 4.8-fold increase in chitotriosidase levels when compared to healthy controls (p<0.001) [86]. YKL-40, a homolog to chitotriosidase was recently described in early stages of AD with significantly higher protein levels found in CSF (p<0.0001) as well as in plasma (p=0.014) compared to controls [87,88], and more importantly, presented a strong ability to predict onset and progression of dementia [87]. For instance, it was found that a high YKL-40/Aβ42 ratio in CSF demonstrated strong predictive values of a faster cognitive decline, and that levels of YKL-40 significantly correlated (r = 0.5948, p<0.0001) with levels of phosphorylated Tau in CSF [87]. Analysis of plasma has some advantages as an approach to population-based screening of AD as it is well accepted and less invasive than CSF sampling, for example. A review of longitudinal studies that examined plasma levels of Aβ indicates that higher baseline levels of Aβ40 might predict higher risk of conversion towards AD [89] and that higher levels of Aβ42 were also associated with a 3-fold increase of AD risk [20]. Importantly, higher level of baseline plasma amyloid in people free of dementia appears to be a predictive marker of a faster cognitive decline in those individuals who converts to AD [90]. An intensive study investigating biomarkers for diagnosis of AD in the Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL) cohort identified a list of 21 plasma-based biomarkers that showed a significant fold change between AD and healthy controls. The top 10 biomarkers with the most differences (p<0.0001) were as follows; insulin like growth factor binding protein 2, pancreatic polypeptide, cortisol, vascular cell adhesion molecule 1, superoxide dismutase, interleukins 10 and 17, albumin, calcium and Zinc (isotope 66) [43]. More recently a study from Mapstone et al. [91] discovered and validated a list of 10 phospholipid fatty acids that were depleted in healthy controls who would
convert to MCI or AD within a 2-3 year timeframe. This panel of metabolites was still
depleted after conversion and allowed separation of converters from controls that remained
cognitively normal with more than 90% accuracy. Importantly, the ROC curve generated in
their study showed an area under the curve (AUC) of 0.96 and a specificity and sensitivity of
both 90% [91]. The evidence discussed above suggests that AD is a systemic disorder
involving a change in a myriad of biological parameters that can be reflected in peripheral
tissues.

3. **Focus on buccal cells as a peripheral tissue**

Buccal mucosa (BM), like the brain and skin epithelium cells, are derived from differentiated
ectodermal tissue during embryogenesis and therefore would be a potential surrogate non-
neural tissue that may have the potential to reflect the underlying pathological changes
observed in AD. Buccal cells have been used as a source of tissue in a variety of biochemical
and molecular biology studies using an assortment of different techniques to collect the cells
including; cotton swabs [92], cytobrushes [92-94], a “swish and spit” method [95-97], a
modified Guthrie card [98] and a method of rubbing cheeks against teeth to exfoliate cells
[94]. The results from those studies demonstrated that high quantities of buccal cells (more
than a million per sampling) could be obtained and then subsequently used in a variety of
assays; such as DNA analysis using PCR or other genotype tests [95,96,99-102], for isolation
of mRNA for gene expression profiling, Western blots for detection of proteins and
immunocytochemistry [103-105], high-performance liquid chromatography (HPLC) [106] and
ion transporter assays [107]. Ideally invasive procedures should be avoided in AD patients
due to age and presenting medical issues, therefore buccal cells could offer an appropriate
alternative as a relatively non-invasive and easily accessible source of tissue for analysis.
Furthermore, buccal cells have been shown to be osmotically stable in hypotonic solutions
including water [108] making them more easily processed with less risk of losing intracellular
contents during investigation procedures. Additionally, it has been found that buccal cells can be readily preserved during transportation for cytology and immunocytochemistry studies by isolation directly into buccal cell buffer [109]. Therefore it would be possible to isolate buccal cells from patients in remote regions and facilitate storage of samples in laboratories.

3.1. Morphological changes in buccal cells

For the BM to be a valuable tissue to study for biomarkers of AD, the BM would need to exhibit changes within the cells that correlate well with the disease state. Structurally, the BM is a stratified squamous epithelium consisting of four distinct layers [110-112] as shown in Figure 1. First the stratum corneum lines the oral cavity. Below this layer, is located the stratum granulosum, and the stratum spinosum containing populations of differentiated, apoptotic and necrotic cells. The next layer contains the rete pegs or stratum germinativum composed of basal cells, which, by cell division and DNA replication regenerate and maintain the profile, structure and integrity of the BM [113]. The basal cells are believed to differentiate and migrate to the keratinized surface layer in 7 to 21 days. With normal ageing the efficiency of cell regeneration decreases [112,114] resulting in a thinner epidermis and underlying cell layers [115]. The protective function of the stratum corneum is not altered [116] but the rete pegs adopts a more flattened appearance [117,118].

Since buccal cells and the nervous system are derived from the same germ cell layer, the ectoderm, the regenerative potential of BM might be affected in parallel with the regenerative potential of the brain, which is found to be altered in AD [119]. One study investigated the BM’s different cell types and its composition in AD compared with age-matched controls by the use of the buccal cytome assay [120]. Frequencies of the various cell types were scored and an alteration of the BM composition was shown to occur in AD. A
significant decrease in the frequency of basal cells, karyorrhectic and condensed chromatin cells (p<0.0001) were found in the AD cohort [120] as shown in Figure 2. The odds ratio of being diagnosed with AD for a combined karyorrhectic and basal cell frequency of <41 per 1000 cells was shown to be 140 with a specificity of 96.8% and a sensitivity of 82.4% [120]. This segregation of cell types has also been shown in an automated manner using imaging analysis by laser scanning cytometry (LSC) [121], making this cytome assay more feasible for scoring on a larger study scale. Another study [122], aimed at assessing morphologic and cytometric aspects of cells of the oral mucosa of AD patients using the Papanicolaou staining method [123]. A visual assessment of cell types was made by microscopy and cytological parameters were measured using the Image J analysis software. The results of that study demonstrated a significant reduction in the number of intermediate cells (p<0.05) as well as in the nuclear:cytoplasmic area ratio (p<0.0001) in the AD group compared to the controls [122]. Both studies suggest that changes occur in the BM of those diagnosed with AD in terms of cytological features and cell type composition which may indicate a decrease in the regenerative capacity of the BM in AD.

3.2. Cytokeratins – Biochemical cell type segregation

The frequency of basal buccal cells as discussed in the previous section was found to be lower in AD, using the buccal cytome assay, which scores cells on morphological features. Therefore, an epithelial cell differentiation marker may allow a more definite and precise identification of basal cells, as compared with visual assessment by the buccal cytome assay. Indeed, buccal cells contain groups of structural proteins called cytokeratins (CK) [124], that are found to be expressed in a tissue specific manner [125,126]. Buccal cells normally express CK 4, 5, 13, 14 and possibly 19 depending on their cell types [125,127]; CK5 and CK14 are predominantly expressed in the basal layer but after a period of differentiation and migration, buccal cells begin expressing CK4 and CK13 accompanied with a progressively
reduced expression of CK5 and CK14 [128]. Furthermore, in other epithelial tissues such as
the olfactory epithelium, basal cells were shown to express keratin 8 [129]. An example of
the differences in cytokeratin immunostaining of buccal cells observed by our group is
shown in Figure 3, where some cells were found to be positive for CK5 or CK13, others were
both CK5 and CK13 positive, whilst yet another population of buccal cells were negative for
CK5 and CK13 (Figure 3). Another study also showed that CK10 and CK8 were detected in
low amounts in buccal cells using immunocytochemistry techniques [128]. Interestingly,
differential expression of CK proteins, such as CK5, has been observed in carcinomas of the
BM [127,130]. For instance, in mucoepidermoid carcinoma there was a strong correlation of
high levels of CK5 expression (in oral mucosa) with poorer survival times (p<0.001).
Specifically, at the completion of that study, 12 (of 13) patients with high levels of CK5
expression were deceased, compared with 6 patients out of the 18 patients with the lowest
values of CK5 expression [130]. In another study investigating dementia, levels of keratin
autoantibodies when quantified by enzyme-linked immunosorbent assay (ELISA) in serum
from patients with dementia, including 68% of patients diagnosed with AD, were found to be
significantly increased compared to healthy controls (p<0.05) [131]. It was speculated that
the increase in presentation of the keratin antigen to the immune-competent cells may
result from the degenerative process of the brain. Since CK expression has been widely
shown to differ in the BM with cell types [125,127], developmental stage [132,133], tissue
differentiation [126,134-138] and pathological conditions [139-145], CK proteins could
provide information on the proliferation and differentiation status which may be dependent
on the disease state. Furthermore CK staining of BM may offer a convenient
immunocytochemical manner of identifying cell types which could be scored in a
quantitative and automated manner in AD patients using cellular imaging techniques such as
laser scanning cytometry.
3.3. Buccal cells and Tau

Accumulation of Tau forming neurofibrillary tangles (NFTs) in the brain is one of the main hallmarks of AD and has a major role in neuronal death. Hattori et al. [103] demonstrated the presence of putative multiple isoforms of Tau on Western blots that were the non-phosphorylated form of Tau protein in buccal cells with the prominent appearance of two bands at approximately 65 kDa and 110 kDa, using the monoclonal BT-2 antibody. Using ELISA techniques, total Tau protein was shown to be significantly elevated within buccal cells of AD compared with age-matched controls (p<0.01). Furthermore, the increase in Tau of oral epithelium was shown to be significantly correlated with the Tau level in CSF (r = 0.43, p=0.011) and was also higher in AD subjects when diagnosed at a younger age of onset than with patients at later age of onset [103]. Therefore it is feasible that oral epithelium Tau may be a measurable and useful predictive biomarker of AD in buccal cells; however this unique observation has not been verified yet in other studies and awaits replication.

3.4. Buccal cells and Amyloid

Aβ is the main component of senile plaques appearing in the brains of AD and is generated by the processing of its precursor AβPP. Since AβPP is ubiquitously expressed, it may be involved in stimulation and proliferation of keratinocytes where they are mostly expressed in the basal layer [146]. It is feasible that differences of AβPP expression in the BM could therefore also reveal information regarding the regeneration potential of the BM in AD. The expression of AβPP was shown to be present in the buccal pouch of hamsters and AβPP is believed to promote the development of oral carcinogenesis [147]. The biopsy of oral tissues for instance has been advocated as an alternate method of detecting amyloid deposition in amyloidosis [148] confirming that amyloid can accumulate to detectable levels in peripheral tissue such as the liver in systemic amyloidosis [149]. AβPP has previously been investigated in young adult Wistar rats and localized by immunohistochemistry in several peripheral
tissues, i.e. liver, kidney, spleen, pancreas, salivary gland, testis and ovary [150]. Since AβPP is a protein ubiquitously expressed in humans, it is likely that Aβ protein which is processed from AβPP and its’ variants (e.g. monomers, dimers, oligomers, etc...) may be a plausible target to be investigated in the BM of AD patients [151]. It is plausible that a genetic or acquired predisposition for amyloidogenic processing of AβPP could be evident not only in the brain but also in epithelial tissues.

3.5. Buccal cells and DNA damage

Genomic DNA damage has been shown to be associated with AD as discussed earlier [152]. Genomic instability has been reported to increase with age and therefore the capacity for DNA damage repair may also be altered [24-26]. In buccal cells a buccal micronucleus cytome assay was developed by Thomas et al. to score DNA damage, cell death and regenerative potential [120,153]. A Down’s syndrome cohort was used as a model for premature ageing and presented a significantly elevated level of MN compared with both the older and younger control groups (p<0.0001) [154]. The same buccal micronucleus cytome scoring assay was performed on an Alzheimer’s cohort and showed a slightly elevated MN score in the AD group when compared to age-matched controls, but this difference did not reach statistical significance [120]. Genomic changes such as aneuploidy of both chromosomes 17 and 21, containing respectively the genes coding for Tau and AβPP [155,156], has also been investigated in buccal cells. Aneuploidy levels of chromosomes 17 and 21 were shown to increase in buccal cells in AD and Down’s syndrome compared to their respective controls [157]. Additionally, DNA double strand breaks have been detected in human buccal cells using an immunofluorescent antibody against γH2AX [158], therefore confirming that MN and γH2AX are two important DNA damage biomarkers that can be detected and may be altered in buccal cells from patients with AD. Oxidative stress has also been studied in leukocytes and exfoliated BM using HPLC after DNA isolation [106] and
because the association between accumulated oxidative DNA damage and ageing is well documented, it is possible that the BM may show changes in 8-OHdG levels from AD buccal samples; however this has yet to be tested.

3.6. Buccal cells and cytological parameters

In a recent study from our group, an automated buccal cell assay was developed using laser scanning cytometry (LSC) to measure buccal cell neutral lipid, nuclear DNA content and nuclear shape from clinically diagnosed AD, MCI patients and age- and gender-matched controls [109]. Findings showed significantly lower levels of neutral lipids in MCI and a significant increase in DNA content in both MCI and AD compared to controls. The ploidy distribution of nuclei was also investigated in this study and showed that the increase in DNA content observed in MCI and AD cases were due to a significant decrease in the proportion of 2N nuclei with a concomitant increase in the proportion of >2N nuclei. Additionally, the LSC automated buccal cell assay developed by our group allowed collection of “circularity” measurements providing information on the shape of buccal cell nuclei. It was found that nuclei had a significantly more irregular shape in MCI and AD when compared to controls [109]. These results suggest that the changes in DNA content are due to hyperdiploid nuclei accumulating with the disease state. ROC curves were also used in this study for each of the parameters analysed and their combination, generating AUC varying from 0.763 to 0.837 [109]. It would therefore be of interest to combine this automated assay with detection of other potential specific protein markers, which may increase the likelihood of better predictive markers for AD.

3.7. Buccal cells and telomere length

Absolute telomere length has been investigated in buccal cells of confirmed AD cases and healthy age- and gender-matched controls. A significantly shorter telomere length was
observed in buccal cells of the AD group compared to controls (p=0.01). Additionally, in the same individuals, there was a significant decrease in telomere length in white blood cells (p<0.0001) [19]. However there was no correlation between buccal cell and lymphocyte telomere length. This may be partly due to the differences in turnover rates of cell division in buccal cells compared with lymphocytes. Although the evidence is minimal to-date, buccal cells and lymphocytes appear to exhibit a reduction in telomere length in AD and therefore, suggest that other peripheral tissues inducing BM may also be used to assess reductions in telomere length in AD.

4. Future perspectives

As populations throughout the world continue to age, the prevalence of AD is expected to increase dramatically. By 2050 nearly one million new AD cases per year has been estimated, with this increasing prevalence becoming a global concern threatening to impact heavily on both social and economic levels [10,159-161]. Therefore biomarkers for an early diagnostic of the disease would tremendously benefit the community as treatment strategies would likely to be more effective in preserving brain function if administered early in the disease process prior to the development of symptoms. Evidence that pathologic changes of AD are reflected in peripheral tissues such as fibroblasts, olfactory epithelium, whole blood, platelets, white blood cells and plasma indicates that AD is a systemic disorder and that these tissues should be considered as a useful source for potential biomarkers (see Table 1). However, investigating a minimally invasive tissue such as the BM as a source of biomarkers with high specificity and sensitivity for AD is yet to be achieved. The BM is an easily accessible non neuronal tissue, which offers a simple, painless and non-expensive sampling procedure. Previous findings suggest that the regenerative potential of the buccal mucosa varies and cytological changes occur within buccal cells following the appearance of AD. However there is still little known in this area regarding buccal cell differentiation and
proliferation status. Only a few studies have investigated changes in the oral mucosa in AD investigating cytological parameters, cell type composition, qualification of Tau, MN, DNA content, lipids, telomere length as well as chromosome 17 and 21 aneuploidy (see Table 1) confirming that the BM is a potential tissue for AD diagnostic biomarkers. Therefore, further research must be undertaken in order to obtain a better understanding of the biology of buccal cells, to replicate such studies and investigate other potential markers of AD that might include lipid content, APOE gene expression, AβPP, Aβ, γH2AX, 8-OHdG as well as others. Longitudinal studies could then be undertaken to capture the variation in biomarkers with the progression of the disease and the associated cognitive decline. This review summarizes some of the knowledge gaps in buccal cells as a peripheral tissue for AD diagnostics. If combined with results from other peripheral tissues, new biomarker sets could emerge that may identify individuals who are at increased risk or are at an early stage of AD with much higher certainty. Therefore, investigations involving minimally invasive non-neural tissue for sampling biomarkers cellular origin of MCI/AD risk need to be further investigated.

5. Acknowledgements

Financial support from the CSIRO’s Preventative Health Flagship is gratefully acknowledged. This project was part funded by a grant from The JO & JR Wicking Trust, which is managed by ANZ Trustees (Australia).
References

[1] Alzheimer’s Association, Thies W, Bleiler L. 2011 Alzheimer’s disease facts and figures. Alzheimers Dement 2011 Mar;7(2):208-244.

[2] Marin DB, Green CR, Schmeidler J, Harvey PD, Lawlor BA, Ryan TM, et al. Noncognitive disturbances in Alzheimer’s disease: frequency, longitudinal course, and relationship to cognitive symptoms. J Am Geriatr Soc 1997 Nov;45(11):1331-1338.

[3] Fernandez M, Gobartt AL, Balana M, COOPERA Study Group. Behavioural symptoms in patients with Alzheimer’s disease and their association with cognitive impairment. BMC Neurol 2010 Sep 28;10:87.

[4] Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007 Jan;14(1):e1-26.

[5] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 May;7(3):263-269.

[6] Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009 Dec;66(12):1447-1455.

[7] Armstrong RA. Plaques and tangles and the pathogenesis of Alzheimer’s disease. Folia Neuropathol 2006;44(1):1-11.
[8] Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012 May;71(5):362-381.

[9] Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013 Jan;9(1):63-75.e2.

[10] Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, et al. The public health impact of Alzheimer’s disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002;23:213-231.

[11] Wimo A, Jonsson L, Bond J, Prince M, Winblad B, Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013 Jan;9(1):1-11.e3.

[12] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001 Mar;69(3):89-95.

[13] Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008 Oct;65(10):1304-1309.

[14] Cairns NJ, Ikonomovic MD, Benziinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical,
cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009 Dec;66(12):1557-1562.

[15] Blennow K, Zetterberg H. Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers Dis 2009;18(2):413-417.

[16] Prvulovic D, Hampel H. Amyloid beta (Abeta) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin Chem Lab Med 2011 Mar;49(3):367-374.

[17] Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med 2010 Feb;4(1):65-79.

[18] Hampel H, Prvulovic D. Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective. J Nutr Health Aging 2012 Apr;16(4):346-348.

[19] Thomas P, O'Callaghan NJ, Fenech M. Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer's disease. Mech Ageing Dev 2008 Apr;129(4):183-190.

[20] Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A 2008 Sep 16;105(37):14052-14057.
[21] Arnold SE, Lee EB, Moberg PJ, Stutzbach L, Kazi H, Han LY, et al. Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol 2010 Apr;67(4):462-469.

[22] Migliore L, Coppede F, Fenech M, Thomas P. Association of micronucleus frequency with neurodegenerative diseases. Mutagenesis 2011 Jan;26(1):85-92.

[23] Neumann K, Farias G, Slachevsky A, Perez P, Maccioni RB. Human platelets tau: a potential peripheral marker for Alzheimer's disease. J Alzheimers Dis 2011;25(1):103-109.

[24] Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2'-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci U S A 1990 Jun;87(12):4533-4537.

[25] Goukassian D, Gad F, Yaar M, Eller MS, Nehal US, Gilchrest BA. Mechanisms and implications of the age-associated decrease in DNA repair capacity. FASEB J 2000 Jul;14(10):1325-1334.

[26] Wilson DM,3rd, Bohr VA, McKinnon PJ. DNA damage, DNA repair, ageing and age-related disease. Mech Ageing Dev 2008 Jul-Aug;129(7-8):349-352.

[27] Bonassi S, Znaor A, Ceppi M, Lando C, Chang WP, Holland N, et al. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 2007 Mar;28(3):625-631.
[28] Murgia E, Maggini V, Barale R, Rossi AM. Micronuclei, genetic polymorphisms and cardiovascular disease mortality in a nested case-control study in Italy. Mutat Res 2007 Aug;621(1-2):113-118.

[29] Petrozzi L, Lucetti C, Scarpato R, Gambaccini G, Trippi F, Bernardini S, et al. Cytogenetic alterations in lymphocytes of Alzheimer’s disease and Parkinson’s disease patients. Neurol Sci 2002 Sep;23 Suppl 2:S97-8.

[30] Federici C, Botto N, Manfredi S, Rizza A, Del Fiandra M, Andreassi MG. Relation of increased chromosomal damage to future adverse cardiac events in patients with known coronary artery disease. Am J Cardiol 2008 Nov 15;102(10):1296-1300.

[31] Antoccia A, Tanzarella C, Modesti D, Degrassi F. Cytokinesis-block micronucleus assay with kinetochore detection in colchicine-treated human fibroblasts. Mutat Res 1993 May;287(1):93-99.

[32] Trippi F, Botto N, Scarpato R, Petrozzi L, Bonuccelli U, Latorraca S, et al. Spontaneous and induced chromosome damage in somatic cells of sporadic and familial Alzheimer’s disease patients. Mutagenesis 2001 Jul;16(4):323-327.

[33] Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 1998 Dec;25(9):1044-1048.

[34] Perluigi M, Butterfield DA. Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia. Curr Gerontol Geriatr Res 2012;2012:724904.
[35] Geller LN, Potter H. Chromosome missegregation and trisomy 21 mosaicism in Alzheimer's disease. Neurobiol Dis 1999 Jun;6(3):167-179.

[36] Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001 Feb;3(1):75-80.

[37] Pani A, Dessi S, Diaz G, La Colla P, Abete C, Mulas C, et al. Altered cholesterol ester cycle in skin fibroblasts from patients with Alzheimer's disease. J Alzheimers Dis 2009;18(4):829-841.

[38] Peterson C, Ratan RR, Shelanski ML, Goldman JE. Cytosolic free calcium and cell spreading decrease in fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci U S A 1986 Oct;83(20):7999-8001.

[39] Peterson C, Goldman JE. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci U S A 1986 Apr;83(8):2758-2762.

[40] Yang M, Crawley JN. Simple behavioral assessment of mouse olfaction. Curr Protoc Neurosci 2009 Jul;Chapter 8:Unit 8.24.

[41] Cheng N, Cai H, Belluscio L. In vivo olfactory model of APP-induced neurodegeneration reveals a reversible cell-autonomous function. J Neurosci 2011 Sep 28;31(39):13699-13704.

[42] Perry G, Castellani RJ, Smith MA, Harris PL, Kubat Z, Ghanbari K, et al. Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol 2003 Dec;106(6):552-556.
[43] Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al. Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. Arch Neurol 2012 Jul 16:1-8.

[44] Lee TS, Goh L, Chong MS, Chua SM, Chen GB, Feng L, et al. Downregulation of TOMM40 expression in the blood of Alzheimer disease subjects compared with matched controls. J Psychiatr Res 2012 Jun;46(6):828-830.

[45] Clark LF, Kodadek T. Advances in blood-based protein biomarkers for Alzheimer’s disease. Alzheimers Res Ther 2013 May 9;5(3):18.

[46] Potkin SG, Guffanti G, Lakatos A, Turner JA, Kruggel F, Fallon JH, et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer’s disease. PLoS One 2009 Aug 7;4(8):e6501.

[47] Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, et al. Homocysteine, vitamin B12, and folic acid levels in Alzheimer’s disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimers Dis 2011;27(4):909-922.

[48] Leidinger P, Backes C, Deutscher S, Schmitt K, Muller SC, Frese K, et al. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol 2013 Jul 29;14(7):R78.

[49] Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol 1985 Oct;101(4):1371-1378.
Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 1993 Sep;61(3):921-927.

Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 1995 Aug;65(2):732-738.

Armentero MT, Sinforiani E, Ghezzi C, Bazzini E, Levandis G, Ambrosi G, et al. Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease. Neurobiol Aging 2011 Dec;32(12):2142-2151.

Watabe-Rudolph M, Song Z, Lausser L, Schnack C, Begus-Nahrmann Y, Scheithauer MO, et al. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology 2012 Feb 21;78(8):569-577.

Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Mansson JE, et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 2011 Jun;13(2):151-159.

Di Rosa M, Dell'Ombra N, Zambito AM, Malaguarnera M, Nicoletti F, Malaguarnera L. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia. Eur J Neurosci 2006 May;23(10):2648-2656.

Myung NH, Zhu X, Kruma II, Castellani RJ, Petersen RB, Siedlak SL, et al. Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age (Dordr) 2008 Dec;30(4):209-215.
[57] Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 2005 May;26(5):567-573.

[58] Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995 Apr 26;273(16):1274-1278.

[59] Giasson BI, Ischiropoulos H, Lee VM, Trojanowski JQ. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 2002 Jun 15;32(12):1264-1275.

[60] Migliore L, Coppede F. Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res 2002 Dec;512(2-3):135-153.

[61] Perry G, Nunomura A, Hirai K, Zhu X, Perez M, Avila J, et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med 2002 Dec 1;33(11):1475-1479.

[62] Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001 Aug;60(8):759-767.

[63] Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res 2002 Nov 1;70(3):447-450.
[64] Fenech M, Morley AA. Cytokinesis-block micronucleus method in human lymphocytes: effect of in vivo ageing and low dose X-irradiation. Mutat Res 1986 Jul;161(2):193-198.

[65] Migliore L, Botto N, Scarpato R, Petrozzi L, Cipriani G, Bonuccelli U. Preferential occurrence of chromosome 21 malsegregation in peripheral blood lymphocytes of Alzheimer disease patients. Cytogenet Cell Genet 1999;87(1-2):41-46.

[66] Migliore L, Testa A, Scarpato R, Pavese N, Petrozzi L, Bonuccelli U. Spontaneous and induced aneuploidy in peripheral blood lymphocytes of patients with Alzheimer's disease. Hum Genet 1997 Dec;101(3):299-305.

[67] Bull CF, O'Callaghan NJ, Mayrhofer G, Fenech MF. Telomere length in lymphocytes of older South Australian men may be inversely associated with plasma homocysteine. Rejuvenation Res 2009 Oct;12(5):341-349.

[68] Kimura M, Stone RC, Hunt SC, Skurnick J, Lu X, Cao X, et al. Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths. Nat Protoc 2010 Sep;5(9):1596-1607.

[69] Takubo K, Aida J, Izumiyama-Shimomura N, Ishikawa N, Sawabe M, Kurabayashi R, et al. Changes of telomere length with aging. Geriatr Gerontol Int 2010 Jul;10 Suppl 1:S197-206.

[70] O'Callaghan NJ, Fenech M. A quantitative PCR method for measuring absolute telomere length. Biol Proced Online 2011 Jan 31;13:3.
[71] Samani NJ, Boulty R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet 2001 Aug 11;358(9280):472-473.

[72] Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003 Feb 1;361(9355):393-395.

[73] Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 2003 Aug 20;95(16):1211-1218.

[74] Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, et al. Telomere shortening in T cells correlates with Alzheimer’s disease status. Neurobiol Aging 2003 Jan-Feb;24(1):77-84.

[75] Pani A, Mandas A, Diaz G, Abete C, Cocco PL, Angius F, et al. Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer patients and asymptomatic subjects at risk of disease. BMC Med 2009 Nov 2;7:66.

[76] Brion JP. Immunological demonstration of tau protein in neurofibrillary tangles of Alzheimer’s disease. J Alzheimers Dis 2006;9(3 Suppl):177-185.

[77] Brion JP, Octave JN, Couck AM. Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neurons. Neuroscience 1994 Dec;63(3):895-909.
[78] Copani A, Condorelli F, Caruso A, Vancheri C, Sala A, Giuffrida Stella AM, et al. Mitotic signaling by beta-amyloid causes neuronal death. FASEB J 1999 Dec;13(15):2225-2234.

[79] Iqbal K, Zaidi T, Thompson CH, Merz PA, Wisniewski HM. Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol 1984;62(3):167-177.

[80] Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986 Jul;83(13):4913-4917.

[81] Schubert D, Cole G, Saitoh T, Oltersdorf T. Amyloid beta protein precursor is a mitogen. Biochem Biophys Res Commun 1989 Jul 14;162(1):83-88.

[82] Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, et al. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 1992 Jul;9(1):129-137.

[83] Song J, Wang S, Tan M, Jia J. G1/S checkpoint proteins in peripheral blood lymphocytes are potentially diagnostic biomarkers for Alzheimer's disease. Neurosci Lett 2012 Sep 27;526(2):144-149.

[84] Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol 2002 Jan;59(1):71-75.
[85] Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A. Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Exp Gerontol 2010 Jan;45(1):53-56.

[86] Sotgiu S, Piras MR, Barone R, Arru G, Fois ML, Rosati G, et al. Chitotriosidase and Alzheimer's disease. Curr Alzheimer Res 2007 Jul;4(3):295-296.

[87] Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010 Nov 15;68(10):903-912.

[88] Choi J, Lee HW, Suk K. Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer's disease. J Neurol 2011 Dec;258(12):2181-2185.

[89] Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease. J Alzheimers Dis 2011;26(2):365-375.

[90] Cosentino SA, Stern Y, Sokolov E, Scarmeas N, Manly JJ, Tang MX, et al. Plasma ss-amyloid and cognitive decline. Arch Neurol 2010 Dec;67(12):1485-1490.

[91] Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, Macarthur LH, et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 2014 Apr;20(4):415-418.
[92] Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet 1993 Feb;2(2):159-163.

[93] Garcia-Closas M, Egan KM, Abruzzo J, Newcomb PA, Titus-Ernstoff L, Franklin T, et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev 2001 Jun;10(6):687-696.

[94] King IB, Satia-Abouta J, Thornquist MD, Bigler J, Patterson RE, Kristal AR, et al. Buccal cell DNA yield, quality, and collection costs: comparison of methods for large-scale studies. Cancer Epidemiol Biomarkers Prev 2002 Oct;11(10 Pt 1):1130-1133.

[95] Hayney MS, Poland GA, Lipsky JJ. A noninvasive 'swish and spit' method for collecting nucleated cells for HLA typing by PCR in population studies. Hum Hered 1996 Mar-Apr;46(2):108-111.

[96] Lum A, Le Marchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev 1998 Aug;7(8):719-724.

[97] Feigelson HS, Rodriguez C, Robertson AS, Jacobs EJ, Calle EE, Reid YA, et al. Determinants of DNA yield and quality from buccal cell samples collected with mouthwash. Cancer Epidemiol Biomarkers Prev 2001 Sep;10(9):1005-1008.
[98] Harty LC, Garcia-Closas M, Rothman N, Reid YA, Tucker MA, Hartge P. Collection of buccal cell DNA using treated cards. Cancer Epidemiol Biomarkers Prev 2000 May;9(5):501-506.

[99] Myerson S, Hemingway H, Budget R, Martin J, Humphries S, Montgomery H. Human angiotensin I-converting enzyme gene and endurance performance. J Appl Physiol 1999 Oct;87(4):1313-1316.

[100] de Vries HG, Collee JM, van Veldhuizen MH, Achterhof L, Smit Sibinga CT, Scheffer H, et al. Validation of the determination of deltaF508 mutations of the cystic fibrosis gene in over 11 000 mouthwashes. Hum Genet 1996 Mar;97(3):334-336.

[101] Guangda X, Bangshun X, Xiujian L, Yangzhong H. Apovarepsilon(4) allele increases the risk for exercise-induced silent myocardial ischemia in non-insulin-dependent diabetes mellitus. Atherosclerosis 1999 Dec;147(2):293-296.

[102] Le Marchand L, Lum-Jones A, Saltzman B, Visaya V, Nomura AM, Kolonel LN. Feasibility of collecting buccal cell DNA by mail in a cohort study. Cancer Epidemiol Biomarkers Prev 2001 Jun;10(6):701-703.

[103] Hattori H, Matsumoto M, Iwai K, Tsuchiya H, Miyauchi E, Takasaki M, et al. The tau protein of oral epithelium increases in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2002 Jan;57(1):M64-70.
[104] Michalczyk A, Varigos G, Smith L, Ackland ML. Fresh and cultured buccal cells as a source of mRNA and protein for molecular analysis. BioTechniques 2004 Aug;37(2):262-4, 266-9.

[105] Spivack SD, Hurteau GJ, Jain R, Kumar SV, Aldous KM, Gierthy JF, et al. Gene-environment interaction signatures by quantitative mRNA profiling in exfoliated buccal mucosal cells. Cancer Res 2004 Sep 15;64(18):6805-6813.

[106] Borthakur G, Butryee C, Stacewicz-Sapuntzakis M, Bowen PE. Exfoliated buccal mucosa cells as a source of DNA to study oxidative stress. Cancer Epidemiol Biomarkers Prev 2008 Jan;17(1):212-219.

[107] Patten GS, Leifert WR, Burnard SL, Head RJ, McMurchie EJ. Stimulation of human cheek cell Na+/H+ antiporter activity by saliva and salivary electrolytes: amplification by nigericin. Mol Cell Biochem 1996 Jan 26;154(2):133-141.

[108] Lee EJ, Patten GS, Burnard SL, McMurchie EJ. Osmotic and other properties of isolated human cheek epithelial cells. Am J Physiol 1994 Jul;267(1 Pt 1):C75-83.

[109] Francois M, Leifert W, Hecker J, Faunt J, Martins R, Thomas P, et al. Altered cytological parameters in buccal cells from individuals with mild cognitive impairment and Alzheimer’s disease. Cytometry A 2014 Feb 25.

[110] Veiro JA, Cummins PG. Imaging of skin epidermis from various origins using confocal laser scanning microscopy. Dermatology 1994;189(1):16-22.
[111] Masters BR, Gonnord G, Corcuff P. Three-dimensional microscopic biopsy of in vivo human skin: a new technique based on a flexible confocal microscope. J Microsc 1997 Mar;185(Pt 3):329-338.

[112] Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr 2001;(29):7-15.

[113] Squier CA, Johnson NW, Hopps RM. Human Oral Mucosa: Development, Structure and Function Blackwell Scientific 1976:7-44.

[114] Hill MW. Epithelial proliferation and turn over in oral epithelia and epidermis with age. The Effect of Ageing in the Oral Mucosa and Skin. London (UK): Bocca Raton: CRC Press pp. 75-83 (1994).

[115] Hill MW. The structural aspects of ageing in the oral mucosa. The Effect of Ageing in the Oral Mucosa and Skin. London (UK): Bocca Raton: CRC Press pp. 65-74 (1994).

[116] Hull MT, Warfel KA. Age-related changes in the cutaneous basal lamina: scanning electron microscopic study. J Invest Dermatol 1983 Oct;81(4):378-380.

[117] Thomas DR. Age-related changes in wound healing. Drugs Aging 2001;18(8):607-620.

[118] Burns T, Breathnack S, Cox N Eds. Rook's Textbook of Dermatology. Oxford (UK): Blackwell publishing (2004).
Winning TA, Townsend GC. Oral mucosal embryology and histology. Clin Dermatol 2000 Sep-Oct;18(5):499-511.

Thomas P, Hecker J, Faunt J, Fenech M. Buccal micronucleus cytome biomarkers may be associated with Alzheimer's disease. Mutagenesis 2007 Nov;22(6):371-379.

Leifert WR, Francois M, Thomas P, Luther E, Holden E, Fenech M. Automation of the buccal micronucleus cytome assay using laser scanning cytometry. Methods Cell Biol 2011;102:321-339.

de Oliveira RM, Lia EN, Guimaraes RM, Bocca AL, Cavalcante Neto FF, da Silva TA. Cytologic and cytometric analysis of oral mucosa in Alzheimer's disease. Anal Quant Cytol Histol 2008 Apr;30(2):113-118.

Papanicolaou GN. The cell smear method of diagnosing cancer. Am J Public Health Nations Health 1948 Feb;38(2):202-205.

Anderton BH. Intermediate filaments: a family of homologous structures. J Muscle Res Cell Motil 1981 Jun;2(2):141-166.

Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982 Nov;31(1):11-24.
[126] Tseng SC, Jarvinen MJ, Nelson WG, Huang JW, Woodcock-Mitchell J, Sun TT. Correlation of specific keratins with different types of epithelial differentiation: monoclonal antibody studies. Cell 1982 Sep;30(2):361-372.

[127] Vaidya MM, Borges AM, Pradhan SA, Rajpal RM, Bhisey AN. Altered keratin expression in buccal mucosal squamous cell carcinoma. J Oral Pathol Med 1989 May;18(5):282-286.

[128] Clausen H, Moe D, Buschard K, Dabelsteen E. Keratin proteins in human oral mucosa. J Oral Pathol 1986 Jan;15(1):36-42.

[129] Trojanowski JQ, Newman PD, Hill WD, Lee VM. Human olfactory epithelium in normal aging, Alzheimer's disease, and other neurodegenerative disorders. J Comp Neurol 1991 Aug 15;310(3):365-376.

[130] Lueck NE, Robinson RA. High levels of expression of cytokeratin 5 are strongly correlated with poor survival in higher grades of mucoepidermoid carcinoma. J Clin Pathol 2008 Jul;61(7):837-840.

[131] Schott K, Wormstall H, Dietrich M, Klein R, Batra A. Autoantibody reactivity in serum of patients with Alzheimer's disease and other age-related dementias. Psychiatry Res 1996 Jan 31;59(3):251-254.

[132] Banks-Schlegel SP. Keratin alterations during embryonic epidermal differentiation: a presage of adult epidermal maturation. J Cell Biol 1982 Jun;93(3):551-559.
[133] Moll R, Moll I, Wiest W. Changes in the pattern of cytokeratin polypeptides in epidermis and hair follicles during skin development in human fetuses. Differentiation 1982;23(2):170-178.

[134] Woodcock-Mitchell J, Eichner R, Nelson WG, Sun TT. Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol 1982 Nov;95(2 Pt 1):580-588.

[135] Sun TT, Eichner R, Nelson WG, Tseng SC, Weiss RA, Jarvinen M, et al. Keratin classes: molecular markers for different types of epithelial differentiation. J Invest Dermatol 1983 Jul;81(1 Suppl):109s-15s.

[136] Clausen H, Vedtofte P, Moe D, Dabelsteen E. Keratin pattern in human and buccal and hard palate mucosa. Scand J Dent Res 1983 Oct;91(5):411-413.

[137] Breitkreutz D, Bohnert A, Herzmann E, Bowden PE, Boukamp P, Fusenig NE. Differentiation specific functions in cultured and transplanted mouse keratinocytes: environmental influences on ultrastructure and keratin expression. Differentiation 1984;26(2):154-169.

[138] Schweizer J, Winter H, Hill MW, Mackenzie IC. The keratin polypeptide patterns in heterotypically recombined epithelia of skin and mucosa of adult mouse. Differentiation 1984;26(2):144-153.

[139] Steinert PM, Peck GL, Idler WW. Structural changes of human epidermal alpha-keratin in disorders of keratinization. Curr Probl Dermatol 1980;10:391-406.
Loning T, Staquet MJ, Thivolet J, Seifert G. Keratin polypeptides distribution in normal and diseased human epidermis and oral mucosa. Immunohistochemical study on unaltered epithelium and inflammatory, premalignant and malignant lesions. Virchows Arch A Pathol Anat Histol 1980;388(3):273-288.

Staquet MJ, Viac J, Thivolet J. Keratin polypeptide modifications induced by human papilloma viruses (HPV). Arch Dermatol Res 1981;271(1):83-90.

Matoltsy AG, Matoltsy MN, Cliffel PJ. Characterization of keratin polypeptides of normal and psoriatic horny cells. J Invest Dermatol 1983 Mar;80(3):185-188.

Bowden PE, Wood EJ, Cunliffe WJ. Comparison of prekeratin and keratin polypeptides in normal and psoriatic human epidermis. Biochim Biophys Acta 1983 Feb 28;743(1):172-179.

Winter H, Schweizer J, Goerttler K. Keratin polypeptide composition as a biochemical tool for the discrimination of benign and malignant epithelial lesions in man. Arch Dermatol Res 1983;275(1):27-34.

Weiss RA, Eichner R, Sun TT. Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48- and 56-kdalton keratin as molecular markers for hyperproliferative keratinocytes. J Cell Biol 1984 Apr;98(4):1397-1406.
[146] Kummer C, Wehner S, Quast T, Werner S, Herzog V. Expression and potential function of beta-amyloid precursor proteins during cutaneous wound repair. Exp Cell Res 2002 Nov 1;280(2):222-232.

[147] Ko SY, Chang KW, Lin SC, Hsu HC, Liu TY. The repressive effect of green tea ingredients on amyloid precursor protein (APP) expression in oral carcinoma cells in vitro and in vivo. Cancer Lett 2007 Jan 8;245(1-2):81-89.

[148] Stoopler ET, Sollecito TP, Chen SY. Amyloid deposition in the oral cavity: a retrospective study and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003 Jun;95(6):674-680.

[149] Lovat LB, Persey MR, Madhoo S, Pepys MB, Hawkins PN. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut 1998 May;42(5):727-734.

[150] Beer J, Masters CL, Beyreuther K. Cells from peripheral tissues that exhibit high APP expression are characterized by their high membrane fusion activity. Neurodegeneration 1995 Mar;4(1):51-59.

[151] Kimberly WT, Zheng JB, Town T, Flavell RA, Selkoe DJ. Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J Neurosci 2005 Jun 8;25(23):5533-5543.

[152] Thomas P, Fenech M. A review of genome mutation and Alzheimer’s disease. Mutagenesis 2007 Jan;22(1):15-33.
[153] Thomas P, Holland N, Bolognesi C, Kirsch-Volders M, Bonassi S, Zeiger E, et al. Buccal micronucleus cytome assay. Nat Protoc 2009;4(6):825-837.

[154] Thomas P, Harvey S, Gruner T, Fenech M. The buccal cytome and micronucleus frequency is substantially altered in Down's syndrome and normal ageing compared to young healthy controls. Mutat Res 2008 Feb 1;638(1-2):37-47.

[155] Iqbal K, Grundke-Iqbal I, Smith AJ, George L, Tung YC, Zaidi T. Identification and localization of a tau peptide to paired helical filaments of Alzheimer disease. Proc Natl Acad Sci U S A 1989 Jul;86(14):5646-5650.

[156] Koo EH. The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog? Traffic 2002 Nov;3(11):763-770.

[157] Thomas P, Fenech M. Chromosome 17 and 21 aneuploidy in buccal cells is increased with ageing and in Alzheimer's disease. Mutagenesis 2008 Jan;23(1):57-65.

[158] Gonzalez JE, Roch-Lefevre SH, Mandina T, Garcia O, Roy L. Induction of gamma-H2AX foci in human exfoliated buccal cells after in vitro exposure to ionising radiation. Int J Radiat Biol 2010 Sep;86(9):752-759.

[159] Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull 2008 Jun;29(2 Suppl):S143-72.
[160] Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005 Dec 17;366(9503):2112-2117.

[161] Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013 Mar;9(2):208-245.
| Peripheral tissue investigated | Parameters measured and outcome | Reference(s) |
|-------------------------------|--------------------------------|--------------|
| Fibroblast                    | 3-fold ↑ MN frequency          | [32]         |
|                               | 2-fold ↑ Trisomy 21 levels     | [35]         |
|                               | 1.3-fold ↑ Immunostaining of amyloid peptides (Aβ_{40}, Aβ_{42}) |          |
|                               | 1.3-fold ↓ β-Secretase 1       | [37]         |
|                               | 6-fold ↑ Rate of cholesterol esterification after 48 h |          |
|                               | 56% ↑ pool of neutral lipids   |              |
|                               | Altered pattern of spreading in culture | [38] |
|                               | 70% ↓ Free calcium content     |              |
|                               | 197% ↑ Bound calcium content   | [39]         |
| Whole blood                   | TOMM40 alleles ↑ disease risk by 2 | [46] |
|                               | 10% ↓ Red blood cell folate    | [47]         |
|                               | AD signature of 12 mi-RNAs identified, compared with controls (95% specificity / 91.5% sensitivity) | [48] |
| White blood cell              | 31% ↓ Telomere length          | [19]         |
| Lymphocyte                    | ↑ Neutral lipid accumulation   | [75]         |
|                               | 2-fold ↑ Total Tau             | [52]         |
|                               | ↑ MN frequency in chromosomes 13 and 21 | [22,65,66] |
|                               | 1.15-fold ↓ Telomere length correlated with ↓ MMSE scores (r = -0.77) | [74] |
|                               | ↑ G1/S checkpoint proteins (Cyclin E, Rb, CDK2 and | [83] |
| Cells         | Changes                                                                 | Literature |
|--------------|-------------------------------------------------------------------------|------------|
| **E2F-1**    |                                                                         |            |
| **Leukocyte**| 2-fold ↑ Single and double strand breaks combined                        |            |
|              | 2.6-fold ↑ DNA oxidized pyrimidines                                      | [57]       |
|              | 2-fold ↑ DNA oxidized purines                                            |            |
| **Macrophage**| 19-fold ↑ Chitotriosidase expression level                               | [55]       |
| **Platelet** | 2.1-fold ↓ AβPP Isoforms (130kDa/110kDa) ratio in platelet membranes    | [84,85]    |
|              | 6.5-fold ↓ High kDa/Low kDa forms of Tau ratio                           | [23]       |
| **Plasma**   | ↑ Aβ in individuals who further convert to AD                            | [89]       |
|              | ↑ Aβ_{42} predicts ↑ AD risk                                             | [20]       |
|              | ↑ Aβ predicts faster cognitive decline                                    | [90]       |
|              | ↑ Insulin growth factor binding protein 2, pancreatic polypeptide, cortisol, vascular cell adhesion molecule, superoxide dismutase, interleukin 10 | [43]       |
|              | ↓ Albumin, Calcium, Zinc (isotope 66), interleukin 17                    |            |
|              | 4.8-fold ↑ Chitotriosidase level                                         | [86]       |
|              | 3.7-fold ↑ YKL-40 level                                                 | [88]       |
|              | 10 lipids panel predicting conversion to MCI or AD                       | [91]       |
|              | ROC curve AUC value was 0.96                                             |            |
| **Nasal cell**| 3.7-fold ↑ Abundance ratings for Aβ and 1.8-fold ↑ for phosphorylated Tau | [21]       |
|              | 1.2-fold ↑ HNE-pyrrole and 1.5-fold ↑ Heme oxygenase-1                  | [42]       |
| **Buccal cell**| ↓ Frequencies of basal, karyorrhectic and condensed chromatin cells     | [120]      |
| Change in Measurement | Description                                      | Reference(s) |
|-----------------------|--------------------------------------------------|--------------|
| 1.24-fold ↓          | Nuclei/Cytoplasmic size ratio in intermediate cells | [122]         |
| 1.5-fold ↓           | Intermediate cell frequency                      |              |
| ↑ MN frequency in Down's syndrome |                                                   | [121,154]     |
| 1.75-fold ↑          | Tau correlated (r = 0.43) with ↑ Tau in CSF       | [103]         |
| 1.2-fold ↑           | Aneuploidy levels of chromosome 17                | [157]         |
| 1.5-fold ↑           | Aneuploidy levels of chromosome 21                |              |
| 2-fold ↓             | Telomere length                                  | [19]          |
| 1.7-fold ↑ and 1.5-fold ↑ | DNA content in MCI and AD, respectively          |              |
| 1.5-fold ↓           | Neutral lipid content in MCI                      | [109]         |
| 1.7-fold ↓ and 1.5-fold ↓ | 2N nuclei population in MCI and AD, respectively |              |
| ↑ irregular nuclear shape |                                                   |              |

**Abbreviations:** Aβ, Amyloid-β; AD, Alzheimer’s disease; AβPP, Amyloid-β protein precursor; CSF, Cerebrospinal fluid; mi-RNAs, microRNAs; MMSE, Mini-mental state examination; MN, Micronuclei.
Figure 1.
Figure 2.
Figure 3.
Francois et al.

Figure legends

Figure 1: Diagrammatic representation of a cross section of normal buccal mucosa.
The schematic is illustrative of a healthy individual’s buccal mucosa, highlighting the
different cell layers and possible spatial relationships of the various cell types present.

Figure 2: Changes in the buccal cytome are associated with AD.
The frequency (%) of different buccal cell types scored for AD (n=31) and their age- and
gender-matched controls (n=31); for (A) condensed chromatin cells, (B) basal cells and (C)
karyorrhectic cells. Representative images of the buccal cell nuclei (which are one of the
parameters used to define the buccal cytome in addition to the cytoplasm area and staining
intensity) are shown as insets within each graph. Abbreviations: AD, Alzheimer’s disease;
Data are Mean +/- SD. ****p<0.0001. Adapted from Thomas et al. 2007 [120].

Figure 3: Immunocytochemistry techniques showed a difference in expression of
Cytokeratin 5 and 13 within buccal cells.
(A) Schematic showing the differential expression of cytokeratins within the buccal cell
layers. (B) Cytokeratin 5 and 13 were detected using an immunocytochemistry dual-staining
technique, cells expressing cytokeratin 13 were detected with a secondary antibody 488
Alexa Fluor (Green) and cells expressing cytokeratin 5 were detected with a secondary
antibody 647 Alexa Fluor (Red). (C) Using Laser Scanning Cytometry different populations of
cells were scored depending on the type of cytokeratin expressed. (D) From the scattergram
in (C), the percentage of buccal cell types based on cytokeratin 5/13 expression is shown.